Abstract

The development of novel anti-infectives against Kinetoplastids pathogens targeting proteins is a big problem occasioned by the antigenic variation in these parasites. This is also a global concern due to the zoonosis of these parasites, as they infect both humans and animals. Therefore, we need not only to create novel antibiotics, but also to speed up the development pipeline for these antibiotics. This may be achieved by using novel drug targets for Kinetoplastids drug discovery. In this study, we focused our attention on motifs of rRNA molecules that have been created using homology modeling. The RNA is the most ambiguous biopolymer in the kinetoplatid, which carries many different functions. For instance, tRNAs, rRNAs, and mRNAs are essential for gene expression both in the pro-and eukaryotes. However, all these types of RNAs have sequences with unique 3D structures that are specific for kinetoplastids only and can be used to shut down essential biochemical processes in kinetoplastids only. All these features make RNA very potent targets for antibacterial drug development. Here, we combine in silico methods combined with both computational biology and structure prediction tools to address our hypothesis. In this study, we outline a systematic approach for identifying kinetoplastid rRNA-ligand interactions and, more specifically, techniques that can be used to identify small molecules that target particular RNA. The high-resolution optimized model structures of these kineoplastids were generated using RNA 123, where all the stereochemical conflicts were solved and energies minimized to attain the best biological qualities. The high-resolution optimized model’s structures of these kinetoplastids were generated using RNA 123 where all the stereochemical conflicts were solved and energies minimized to attain the best biological qualities. These models were further analyzed to give their docking assessment reliability. Docking strategies, virtual screening, and fishing approaches successfully recognized novel and myriad macromolecular targets for the myxobacterial natural products with high binding affinities to exploit the unmet therapeutic needs. We demonstrate a sensible exploitation of virtual screening strategies to 18S rRNA using natural products interfaced with classical maximization of their efficacy in phamacognosy strategies that are well established. Integration of these virtual screening strategies in natural products chemistry and biochemistry research will spur the development of potential interventions to these tropical neglected diseases.

Highlights

  • Kinetoplastids are a group of flagellated protozoans that are distinguished by the presence of a DNA-containing region, known as a “kinetoplast,” in their single large mitochondrion

  • After phylogenetic analysis and sequence alignment of all the genomes of the selected kinetoplastid species, the sequences were selected based on the completeness of each of the 18S sequenced genes deposited in the verified databases

  • It is important to note that the 18S ribosomal RNA (rRNA) structure is very conserved, with minimal allowed changes in the expansion segments, and since this is a single species, not much variation is expected

Read more

Summary

Introduction

Kinetoplastids are a group of flagellated protozoans that are distinguished by the presence of a DNA-containing region, known as a “kinetoplast,” in their single large mitochondrion These groups include a number of both animal and plant pathogens that are transmitted through different vectors and cause disease. Leishmaniasis leads with an individual mortality rate of 50,000 per year and an annual loss of 2.1 million disabilityadjusted life years (DALYs) [3]. This is followed by 48,000 deaths caused by HAT (which causes sleeping sickness) with 1.5 million more DALYs annually [1,4]. Despite the concerted efforts to combat these kinetoplastid infections, they continue to pose serious health and economic risks, in endemic regions

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.